Company

Product

Description

Indication

Status

Glaxosmithkline plc, of London

Nucala (mepolizumab)

Anti-IL-5 biologic

Severe eosinophilic asthma or eosinophilic granulomatosis with polyangiitis

Approved in Canada in 2 new formats: prefilled autoinjector and prefilled safety syringe

Glenmark Pharmaceuticals Inc., of Mumbai, India

Dimethyl fumarate delayed-release capsules

Activates Nrf2 pathway

Multiple sclerosis

Received tentative approval from FDA for generic version of Tecfidera (Biogen Inc.)

Notes

For more information about individual companies and/or products, see Cortellis.

 

No Comments